BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 15968542)

  • 1. Palliative management strategies of advanced gastrointestinal carcinoid neoplasms.
    Sartori P; Mussi C; Angelini C; Crippa S; Caprotti R; Uggeri F
    Langenbecks Arch Surg; 2005 Sep; 390(5):391-6. PubMed ID: 15968542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic surgery for metastases from neuroendocrine tumors.
    Sarmiento JM; Que FG
    Surg Oncol Clin N Am; 2003 Jan; 12(1):231-42. PubMed ID: 12735141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors.
    Osborne DA; Zervos EE; Strosberg J; Boe BA; Malafa M; Rosemurgy AS; Yeatman TJ; Carey L; Duhaine L; Kvols LK
    Ann Surg Oncol; 2006 Apr; 13(4):572-81. PubMed ID: 16511671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver.
    Chung MH; Pisegna J; Spirt M; Giuliano AE; Ye W; Ramming KP; Bilchik AJ
    Surgery; 2001 Dec; 130(6):954-62. PubMed ID: 11742323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of liver metastases of carcinoid tumors.
    Ahlman H; Westberg G; Wängberg B; Nilsson O; Tylén U; Scherstén T; Tisell LE
    World J Surg; 1996 Feb; 20(2):196-202. PubMed ID: 8661817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of hepatic metastasis of gastrointestinal carcinoid tumors.
    Landry CS; Scoggins CR; McMasters KM; Martin RC
    J Surg Oncol; 2008 Mar; 97(3):253-8. PubMed ID: 18264984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors.
    Jensen EH; Kvols L; McLoughlin JM; Lewis JM; Alvarado MD; Yeatman T; Malafa M; Shibata D
    Ann Surg Oncol; 2007 Feb; 14(2):780-5. PubMed ID: 17146740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors.
    Søreide O; Berstad T; Bakka A; Schrumpf E; Hanssen LE; Engh V; Bergan A; Flatmark A
    Surgery; 1992 Jan; 111(1):48-54. PubMed ID: 1728075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoreductive surgery in patients with advanced-stage carcinoid tumors.
    Gulec SA; Mountcastle TS; Frey D; Cundiff JD; Mathews E; Anthony L; O'Leary JP; Boudreaux JP
    Am Surg; 2002 Aug; 68(8):667-71; discussion 671-2. PubMed ID: 12206599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors.
    Drougas JG; Anthony LB; Blair TK; Lopez RR; Wright JK; Chapman WC; Webb L; Mazer M; Meranze S; Pinson CW
    Am J Surg; 1998 May; 175(5):408-12. PubMed ID: 9600289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients.
    Massimino K; Harrskog O; Pommier S; Pommier R
    J Surg Oncol; 2013 Jun; 107(8):842-6. PubMed ID: 23592524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors.
    Chambers AJ; Pasieka JL; Dixon E; Rorstad O
    Surgery; 2008 Oct; 144(4):645-51; discussion 651-3. PubMed ID: 18847650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multimodality palliative treatment of (111)In-pentetreotide negative/(123)I-MIBG positive metastatic carcinoid - a case report.
    Dworakowska D; Gueorguiev M; Laji K; Grossman AB
    Endokrynol Pol; 2008; 59(4):342-7. PubMed ID: 18777505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic neuroendocrine hepatic tumors: resection improves survival.
    Musunuru S; Chen H; Rajpal S; Stephani N; McDermott JC; Holen K; Rikkers LF; Weber SM
    Arch Surg; 2006 Oct; 141(10):1000-4; discussion 1005. PubMed ID: 17043278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors.
    Diamandidou E; Ajani JA; Yang DJ; Chuang VP; Brown CA; Carrasco HC; Lawrence DD; Wallace S
    AJR Am J Roentgenol; 1998 Feb; 170(2):339-44. PubMed ID: 9456942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiofrequency ablation treatment of refractory carcinoid hepatic metastases.
    Wessels FJ; Schell SR
    J Surg Res; 2001 Jan; 95(1):8-12. PubMed ID: 11120628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver metastases of digestive endocrine tumours: natural history and response to medical treatment.
    Skinazi F; Zins M; Menu Y; Bernades P; Ruszniewski P
    Eur J Gastroenterol Hepatol; 1996 Jul; 8(7):673-8. PubMed ID: 8853257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgical management of carcinoid tumors: role of debulking and surgery for patients with advanced disease.
    Norton JA
    Digestion; 1994; 55 Suppl 3():98-103. PubMed ID: 7535270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Survival with Long-Acting Somatostatin Analogues Plus Aggressive Cytoreductive Surgery in Patients with Metastatic Neuroendocrine Carcinoma.
    Deutsch GB; Lee JH; Bilchik AJ
    J Am Coll Surg; 2015 Jul; 221(1):26-36. PubMed ID: 26027502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors.
    Strosberg JR; Choi J; Cantor AB; Kvols LK
    Cancer Control; 2006 Jan; 13(1):72-8. PubMed ID: 16508629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.